More on KNBWY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kirin Holdings Company, Limited Sponsored Adr (OP:KNBWY)
Delayed: 21.00 -0.15 (0.71%)
Prev. Close $21.15  
Open$20.83 
52 Wk High$18.64 
52 Wk Low$12.59 
Day High$21.00 
Day Low$20.83 
P/E N/A  
EPS$0.00 
Volume23,947 

Friends, Peers and Foes (?): KYKOY, KIR, MEIP, ARDX, 2503:JP (more...)

Jun 10, 2021 05:00 AM Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients
Jun 9, 2021 06:00 AM MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
Jun 7, 2021 08:00 AM MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
Jun 1, 2021 04:00 AM Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
May 19, 2021 05:03 PM MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
May 19, 2021 05:00 PM MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
May 12, 2021 10:02 AM MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
May 12, 2021 10:00 AM MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
May 10, 2021 06:00 AM Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder
May 4, 2021 03:30 PM Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones
View All Articles